Neumune

The Neumune ® is a experimental Médicament intended to look after the Syndrome of acute irradiation whose current treatment is primarily symptomatic. It is developed jointly by the Drug company (Pharmaceuticals Hollis-Eden) and by the American Armée (Radiobiological Research institute of the Armed forces).

Tested at the nonhuman Primate S, it would decrease the Thrombocytopénie and the Anémie resulting from an exposure to radiative amounts moderate and would increase the chances of survival in the event of strong irradiation. At the human healthy one, it would increase the rate of plate S and Neutrophile S in the same way as at the Singe; what pushes the developers to be generalized the result of tested animal with the man.

A special rule of the Food and Drug Administration (FDA) authorizes the marketing of a drug in the absence of test of effectiveness at the human one when that proves to be impossible to realize. In this case it is indeed not possible to expose the human ones to intense amounts of radiations to prove the effectiveness of Neumune. The conditions are that the drug is effective at representative animal species and that the drug is well tolerated by the human being.

See too

Internal bond

Syndrome of acute irradiation

External bond

Neumune on the site of Hollis-Eden Pharmaceuticals

Random links: